You are here

Home » Content

ÇOCUK HEMODİYALİZ HASTALARINDA DİRENÇLİ SEKONDER HİPERPARATİROİDİZM TEDAVİSİNDE İNTRAVENÖZ KALSİTRİOL UYGULAMASI

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Intravenous calcitriol treatment in children with severe secondary hyperparathyroidism. The aim of this study is to assess the efficacy and safety of IV calcitriol treatment in the symptomatic children with secondary hyperparathyroidism (SHPT) who were found to bc nonresponsive to the standart oral calcitriol therapy. Fifteen children (8 boys, 7 girls) with a mcan age of 14.6 ± 3.4 years (range; 11-22 years) undergoİng hemodialysis were enrolled in this study. Ali patients hadreceived Standard oral preparation of calcitriol at a mean dosage of 1.0± 0.3 meg/day for at lcast onc ycar, and ali of tirem had serum intact parathyroid hormone (İPTH) İevels greater than 4 times normal values. After two wceks of wash-out period ali patients were treated with IV calcitriol (CALCIJEX -Abbott Laboratories) for 4 months in an open prospeetive study. The initial dose of calcitriol was 1 meg / three times per week (ie following each hemodialysis) follovved by a dosage modification every 4 weeks according to predialysis caleium (Ca), phosphorus (P) and İPTH ievels (maximum dose was 12 meg per week). Serum Ca, P, alkaline phosphatase (AP) İevels were monitored wcekly, and serum İPTH İevels werc determined monfhly during the study. Serum calcitriol and osteocalcin (OC) İevels were aîso determined at the beginning and at the end of the study. Ali of the 15 children completed their 4 months of IV calcitriol therapy. Symptoms substantially decreased wİthİn the 4th week of treatment and completely resolved by the end of 4th month. İPTH İevels slıowed a significant decrease from 799.5 ± 528.1 pg/ml to 144.2 ± 64.7 pg/ ml at the end of the study. This decrea-se was 78.9 % of baseline İPTH İevels at the fourth monfh. AP İevels decreased from 1454.0 ± 1044.2 IU/1 to 479.1 ± 200.4 IU/1 (p<0.01) in association with the decrease in İPTH. The me-an of basal calcitriol İevels was 20.5 + 3.6 ng/ml and changed to 27.6 ± 10.3 ng/ml (p< 0.05), but this inerease was not in toxic İevels. OC İevels showed a significant decrease from 27.3 ± 6.3 ng/ml to 23.9 ± 7.6 ng/ml, and it was corralated with the inerease of calcitriol İevels. No child in our study had symptoms to suggest adynamic bone disease Hypcrcalcemia was not a significant problem, and İPTH İevels showed an inerease to 244.7± 87.5 pg/ml at the third month after the discontinuation of IV calcitriol therapy. In conelusion, intermittent high dose IV calcitriol treatment İs an effectivc and safe method of PTH supression and relief of renal osteodystrophy (ROD) symptoms without inereasing hypercalcemia risk in the children undergoing hemodialysis wifh refractory SHPT, also provi-ding better patient compliance.
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmanın amacı; son dönem böbrek yetersizliği (SDBY) tanısı ile izlenen ve en az bir yıldır standart oral kalsitirİol tedavisi uygulandığı halde tedaviye dirençli bulunan, semptomatik, persistan sekonder hiperparatİroİdizmli (SHPT) hemodiyaliz tedavisindeki çocuklarda, IV in-termittan kalsitiriol uygulamasının etkinliği ve güvenilirliğinin değerlendirilmesidir. Çalışma grubu; yaş ortalaması 14.6 ± 3.4 yıl {1 î-22 yıl) olan 15 çocuk hastadan (8 erkek, 7 kız) oluştu. Olgularda, en az bir yıldır, 1.0 ± 0.3 meg/gün dozunda oral kalsitirİol kullanımına karşın, parat hormon (İPTH) düzeyieri normalin en az 4 katı yüksekti. Bazal kalsiyum (Ca), fosfor (P), alkali fosfataz (AP), İPTH, osteokalsin (OC), kalsitiriol düzeyleri İçin serum örneği alındıktan sonra, hastalara prospektif olarak dört ay süre iie IV kalsitirİol (CALCIJEX- Abbott Laboratuarı) uygulandı. Çalışma süresince, kalsitiriol doz ayarlaması, dört haftada bir, diyaliz öncesi Ca, P ve İPTH düzeylerine göre yapıldı. Maksimal doz 12 meg/ hafta olarak belirlendi. Dört aylık IV kalsitiriol tedavisinin sonunda olguların tümünde semptomlar düzelirken, İPTH düzeyleri 799.5 ± 528.1 pg/mî den, 144.2 ± 64.7 pg/ml' ye düştü (p<0.001). Bu azalma, bazal düzeye göre 4.ayda %78.9 oranında idi. AP düzeyleri, tedavi başlangıcında 1454.0 ± 1044.2 lU/It idi ve başlangıçta ağır SHPT grubunda yer alan 2 olgu (olgu: 8 vc 11) dışında normal sınırlara inerek tedavinin sonunda 479.1 ± 200.4 IU/lt olarak saptandı (p< 0.001). Tedavi başlangıcında kalsitiriol düzeyi 20.5+3.6 ng/ml iken, tedavi sonunda 27.6+10.3 ng/ml' ye yükseldi (p<0.05). Bir olgu dışında fizyolojik değerlerin üzerine çıkmadı. Tedavi başlangıcında, hemodiyaliz öncesi alınan serum örneklerinde OC düzeyi 27.3+6.3 ng/ml idi ve 4 aylık kalsitiriol tedavisinin sonunda 23.8+7.6 ng/ml' ye düştü. Çalışma süresince hiçbir olguda ağır hiper-kalscmi atağı olmadı, tedavi kesildikten sonraki kontrollerde olgularda adinamik kemik hastalığı düşündüren bulgu saptanmadı. Sonuç olarak IV intermittan kalsitiriol tedavisinin çocuklarda iyi tolere edilen ve ilaç uyumu sorununu ortadan kaldıran, ve dirençli SHPT gelişmiş çocuk hemodiyaliz hastalarında hiper-kalsemİ riskinde artışa neden olmadan İPTH baskılanmasın! sağlayan etkin ve güvenilir bir tedavi olduğunu düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-cocuk-hemodiyaliz-hastalarinda-direncli-sekonder-hiperparatiroidizm-tedavisinde-intravenoz-kalsitriol-uygulamasi.pdf
  • 1
86-93
  • Turkish

REFERENCES

References: 

1. Andıess DL, Norris KC, Coburn JW, ct al. intravenous calcitriol in the treatment of refractory ostcitis fibrosa of chronic renal failure. N Eng J Med 321: 274 (1989).
2. Cannelia G, Bonucci E, Rolfa D, ct al. Evidence of hea-ling of secondary hyperparathyroidism in chronically he-modialysed uretnic patients treated wilh long term intra-venous calcitriol. Kidney Int 46: 1124 (1994).
3. Delmez JA, Tındira C, Grooms P, ct al. PTH supression by intravenous 1,25 dihydroxyvitamin D. A role for inc-reased sensitivity to calcium. J Clin Lnvest 83: Î349 (1989).
4. Dunlay R, Rodriguez M, Felsenfeld A, ct al. Direct inhi-bitory effect of calcitiriol on parathyroid function ( sig-moidal curve) in dialysis. Kidney Int 36: 1093 ( 1989).
5. Fukuda N, Tanaka H, Tominaga Y, et al. Decreascd 1,25 dihydroxy vitamin D3 receptor density is associated with more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin lnvest 92: 1436 (1993).
6. Friedman AL, Heillczer ID, Gundberg CM, ct al. Serum osteocalcin concentration in children with chronic renal faiiure who are not undergoing dialysis. J Pedİalr 116 (2):s55(İ990).
7. Gailieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis palients. Kidney Int 42: 1191 (1992).
8. Gazzero P . Serum osteocalcin in 1634 healthy children. Clinical Chemist 43: 543 (1997).
9. Goodman WG, Ramirez JA, Belin TR, et al. Deveiop-ment of adynamic bone in patients wilh secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160 ( 1994).
10. Hamdy NAT, Ristcİli J, Ristcİlİ L, et al. Serum typc I procollagen peptide: a non-invasive index of bone forma-lion in patients on hemodialysis. Neprol Diai Transplant 9:511 ( 1994).
11. Kilav R, Silver J, Navefı- Many T . PTH gene expression in hypophosphatemic rats. J Clin lnvest 96: 327 (1995).
12. Lcvine BS, Song MM . Pharmacokinctics and efficacy of pulse oral verstıs intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7: 488 ( 1996).
13. Maîberti F, Surian M, Cosci P . Effect of chronic intravenous calcitriol on parathyroid function and set-point of caicium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Trans 7: 822 ( 1992).
14. Mazzeferro S, Cocn G, Ballanti P, et al. Osteocalcin, İPTH, alkaline phosphatasc,hand X-ray scores as predic-tive indices of histomorphometric parameters in renal os-teodystrophy. Nephron 56: 261 (1990).
15. Oetmger CW, Oliver JC, Macon EJ . The effects of caicium carbonate as the sole phosphate binder in combinati-on with Iow calcium dialysate and calcitriol therapy in chronic dialysis patients. S Am Soc Nephrol 3: 995 (1992).
16. Pitts TO, Piraino BH, Mitro R, ct al. Hyperparathyroidism and 1,25 dihydroxyvitamin D deficieney in mild, moderate, and severe renal failure. J Clin Endocrinol Mclab 67: 876 (1988).
17. Portale AA, Holloran BP, Murpy MM, et al. Oral intake phosphorus can determine the serum concenü'ation of 1,25 dihydroxyvitamine D by determining its produetion rale in humans. J Cim lnvest 77: 7 (!986).
18. Çjuarlcs LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710
(1994) .
19. Sanchez CP, Goodman WG, Salusky IB .Osteodys-frophy. In: Barratt TM, Avner ED, Harmon WE (eds) Pe-diatric Nephrology. Baltimore, Lippincott Williams & VVilkins, 123i (1999).
20. Salusky IB, Coburn JW, Folcy J, et al. Effects of oral calcium carbonate on control of serum phsphorus and changes in plasma aluminum İevels after discontiniuation of aluminium containing gels in children rcceiving dialysis. J Pcdiatr 1108: 767 ( 1986).
21. Salusky IB. Bone and mineral melabolism in childhood end-stage renal diseasc. Pcdiatr Clin North America 42: 1531 (1995).
22. Saiusky IB, Goodman WG . The management of renal osteodystrophy. Pediatr Nephrol 10: 651-655.
23. Sherrard DJ (1986) Rcnaî osteodystrophy. Semin Nephrol 6: 56(1996).
24. Sherrard DJ, Hercz G, Pei Y,et al. The speetrum of bone discase in end stage renal disease- an cvolving disorder. Kidney Int 43: 436 (1993).
25. Silver J . Regulation of PTH synthesis and secretion. In: Coe FL, Favus MI ( eds) Disordcrs of bone and mineral melabolism . Raven, New York ( 1992), sayfa: 83.
26. Slatopolsky E, Weerts C, Thielan J, ct al. Marked supression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxy cholecalcipherol in uremic patients. J Clin lnvest 74: 2136 (1984).
27. Sprague SM, Moe SM . Safety and efficacy of long-term treatment of secondary hyperparathyroidism by Iow-dosc intravenous calcitriol. Am J Kidney Dis 19: 532 { 1992).
28. Stcfanovİc V, Mitic M, Golubovic E, et al. Transperito-neal rcmoval of osteocalcin, calcitonin and parathormono in patients treated by CAPD. Nephron 74: 216 (1996).
29. SzaboA, MerkeJ, BeicrE, ctal. 1,25 (OH)2 vitamin D3 inhibits parathyroid celi proliferation in experimental uremia. Kidney Int 35: 1049 (1989).
30. Torres A, Corenzo V, Hernandez D, ct al. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47: 1434
(1995) .

Thank you for copying data from http://www.arastirmax.com